Dalfampridine-ER 10mg ( DrugBank: Dalfampridine )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01535664 (ClinicalTrials.gov)	January 2012	7/2/2012	An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)	An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS	Multiple Sclerosis	Other: Withdrawal of dalfampridine-ER 10mg	Acorda Therapeutics	Prometrika, LLC;BCS Consulting, Inc.	Completed	18 Years	70 Years	All	20		United States
2	NCT01328379 (ClinicalTrials.gov)	March 2011	29/3/2011	Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis	Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Dalfampridine-ER 5mg;Drug: Dalfampridine-ER 10mg;Other: Placebo	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	430	Phase 3	United States